Escitalopram

Escitalopram ((S) -Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ～30 fold higher binding affinity than its R (-) -enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET) . Escitalopram is an antidepressant for the research of major depression[1][2].

Product Specifications

CAS Number

[128196-01-0]

Product Name Alternative

(S) -Citalopram; (S) - (+) -Citalopram

UNSPSC

12352005

Hazard Statement

H302

Target

Serotonin Transporter

Type

Natural Products

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Escitalopram.html

Concentration

10mM

Purity

99.98

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC1=CC=C([C@@]2(CCCN(C)C)C(C=CC(C#N)=C3)=C3CO2)C=C1

Molecular Formula

C20H21FN2O

Molecular Weight

324.39

Precautions

H302

References & Citations

[1]Zhang, P., et al., Structure-activity relationships for a novel series of citalopram (1- (3- (dimethylamino) propyl) -1- (4-fluorophenyl) -1,3-dihydroisobenzofuran-5-carbon itrile) analogues at monoamine transporters. J Med Chem, 2010. 53 (16) : p. 6112-21.|[2]Pastoor, D. and J. Gobburu, Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol, 2014. 10 (1) : p. 121-8.|[3]Wu C , et al. Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity. Neurobiol Aging. 2018;67:137-147.|[4]Cirrito JR, et al. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology. 2020;95 (19) :e2666-e2674.